8-K: GRI BIO Faces Nasdaq Delisting Threat Over Equity Shortfall

GRI BIO, Inc. received a notice from Nasdaq regarding non-compliance with the minimum stockholders' equity requirement, potentially leading to delisting.

Summary

• GRI BIO, Inc. received a notice from The Nasdaq Stock Market LLC on November 26, 2025, indicating non-compliance with the minimum stockholders' equity requirement for continued listing.
• Nasdaq Listing Rule 5550(b)(1) mandates that companies with a market value of listed securities less than $35,000,000 and annual net income less than $500,000 must maintain stockholders' equity of at least $2,500,000.
• The non-compliance is based on information provided in the company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2025.
• The company has 45 calendar days, until January 10, 2026, to submit a plan to regain compliance with the Stockholders Equity Requirement.
• If the Compliance Plan is accepted by Nasdaq Staff, the company may be granted an extension of 180 calendar days from the date of the notice to regain compliance.

Sentiment

Score: 2

Explanation: The filing indicates a significant negative event: non-compliance with Nasdaq listing requirements and the potential for delisting. This introduces substantial uncertainty and risk for investors regarding the company's future public market status and liquidity.

Negatives

• Received a formal notice from Nasdaq regarding non-compliance with the minimum stockholders' equity requirement for continued listing.
• The company's stockholders' equity is below the required $2,500,000 threshold, as indicated by its Q3 2025 10-Q filing.
• Failure to regain compliance could result in the delisting of its common stock from The Nasdaq Capital Market.

Risks

• There is no assurance that the Compliance Plan submitted by the company will be accepted by Nasdaq Staff.
• Even if the Compliance Plan is accepted, there is no assurance that the company will be able to regain compliance with the Stockholders Equity Requirement within the granted extension period.
• The common stock is subject to delisting from The Nasdaq Capital Market if the Compliance Plan is rejected or if compliance is not regained.

Future Outlook

The company plans to submit a Compliance Plan to Nasdaq by January 10, 2026. If this plan is determined to be acceptable, Nasdaq Staff may grant an extension of 180 calendar days from the date of the notice to regain compliance. However, there is no assurance that the Compliance Plan will be accepted or that the company will be able to regain compliance.

Management Comments

• The Company plans to submit a Compliance Plan.

Industry Context

This announcement highlights a company-specific compliance challenge rather than a broader industry trend. However, smaller biotechnology companies often face financial volatility and capital constraints, which can make maintaining stringent listing requirements challenging.

Stakeholder Impact

• Shareholders face significant risk of delisting, which could severely impact the liquidity and valuation of their shares.
• Employees may experience increased uncertainty regarding the company's operational stability and future.

Next Steps

• GRI BIO, INC. must submit a Compliance Plan to Nasdaq by January 10, 2026.
• Nasdaq Staff will review the submitted Compliance Plan for acceptability.
• If the plan is accepted, Nasdaq may grant a 180-calendar-day extension to regain compliance with the Stockholders Equity Requirement.
• If the Compliance Plan is rejected, the company may appeal the Staff's determination to a Nasdaq Hearing Panel.

Key Dates

Recommendation

The notice of non-compliance with Nasdaq's minimum stockholders' equity requirement and the explicit risk of delisting represent a severe negative event. While the company plans to submit a compliance plan, there is no assurance of acceptance or successful remediation. Delisting would significantly impair liquidity and investor confidence, making the stock a high-risk proposition with substantial downside potential. A seasoned investor would likely seek to exit or significantly reduce exposure given this fundamental threat to the company's public market status.

Keywords

GRI BIO, Nasdaq, delisting, stockholders equity, compliance, 8-K filing, listing requirements, financial non-compliance, GRI